EZH2 silencing with RNA interference induces G2/M arrest in human lung cancer cells in vitro
Hui Xia1, Wen Zhang1, Yingjie Li1
1Department of Thoracic-Cardio Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, China.
Abstract:
Nonsmall-cell lung cancer has a high mortality rate and poor prognosis. In the present study, we silenced EZH2 and explored the consequent cell cycle changes. The expression of cell-cycle-related proteins, including p53, p21, Cdc2, and cyclin B1, was detected with western blotting, and the cell cycle distribution was determined with flow cytometry. Inhibition of EZH2 expression changed the cell cycle distribution, in particular inducing G2/M arrest. Expression of Cdc2 and cyclin B1 was significantly decreased in A549 and HTB-56 cells after EZH2-siRNA treatment. In addition, p53 expression was increased by 21% and 18%, and p21 expression was increased by 31% and 23%, in A549 and HTB-56 cells, respectively, in the presence of EZH2-siRNA. This study clearly demonstrates that modulation of EZH2 expression with siRNA affects the cell cycle and the expression levels of p53 and p21, thereby changing cyclin B1 and Cdc2 expression and inducing G2/M arrest. These results may explain the observed antitumor activity of EZH2 silencing. Such explorations of the molecular mechanism of EZH2 will help us develop novel approaches to the diagnosis, treatment, and prevention of nonsmall-cell lung cancer.
Insights
Silencing EZH2 in nonsmall-cell lung cancer cells halts cell cycle progression at G2/M phase. This inhibition increases p53 and p21 levels while decreasing Cdc2 and cyclin B1, suggesting a novel therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Nonsmall-cell lung cancer (NSCLC) presents a significant global health challenge due to its high mortality and poor prognosis.
- Understanding the molecular mechanisms driving NSCLC progression is crucial for developing effective therapeutic interventions.
Purpose of the Study:
- To investigate the effects of silencing Enhancer of Zeste Homolog 2 (EZH2) on cell cycle regulation in NSCLC cells.
- To elucidate the impact of EZH2 inhibition on key cell cycle-related proteins.
Main Methods:
- Utilized small interfering RNA (siRNA) to silence EZH2 expression in NSCLC cell lines (A549 and HTB-56).
- Employed western blotting to detect protein expression levels of p53, p21, Cdc2, and cyclin B1.
- Performed flow cytometry to analyze cell cycle distribution and identify cell cycle arrest.
Main Results:
- EZH2 silencing induced a significant G2/M phase arrest in the cell cycle of NSCLC cells.
- Inhibition of EZH2 led to a notable decrease in the expression of Cdc2 and cyclin B1.
- EZH2-siRNA treatment resulted in increased expression of p53 (21% in A549, 18% in HTB-56) and p21 (31% in A549, 23% in HTB-56).
Conclusions:
- Modulation of EZH2 expression via siRNA effectively alters cell cycle progression, inducing G2/M arrest in NSCLC.
- EZH2 silencing impacts the expression of critical cell cycle regulators, including p53, p21, Cdc2, and cyclin B1.
- These findings provide a molecular basis for the observed antitumor effects of EZH2 silencing and suggest its potential as a therapeutic target for NSCLC.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...